People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Svelte Medical Systems Inc | — | Biotechnology | Series C | $113.1M | $163.7M | 2009 |
| Vascular Therapies Inc | — | Biotechnology | Series B | $89.2M | $471.3M | 2015 |
| Sagent Holding Co. | — | Pharmaceuticals | Series B | $45.8M | $204.0M | 2009 |
| Verax Biomedical Inc | — | Biotechnology | Series A | $45.8M | $91.8M | 2019 |
Robert Flanagan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Flanagan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Somu Subramaniam | 2 | 17 |
| ROBERT CROCE | 2 | 7 |
| Marc Goldberg | 1 | 9 |
| Buzz Benson | 1 | 8 |
| Chen Yu | 1 | 7 |
| Andrew Midler | 1 | 6 |
| David Fischell | 1 | 6 |
| Robert Fischell | 1 | 6 |
| John McDermott | 1 | 5 |
| ROBERT ZIESERL | 1 | 5 |
| Robert E. Fischell | 1 | 5 |
| JOE DEL GUERCIO | 1 | 4 |
| Tim A Fischell | 1 | 4 |
| Phillip D. Torrence | 1 | 4 |
| DAN RYAN | 1 | 4 |
| MARC E. GOLDBERG | 1 | 4 |
| Daniel Ryan | 1 | 4 |
| James Lousararian | 1 | 3 |
| David R. Fischell | 1 | 3 |
| Mark Pomeranz | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.